Evogene Ltd. (NASDAQ:EVGN – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 63,883 shares, a drop of 93.2% from the September 30th total of 932,725 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average trading volume of 244,058 shares, the short-interest ratio is presently 0.3 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research note on Friday, October 2nd. One analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on Evogene
Evogene Stock Performance
EVGN stock traded up $0.01 during trading on Monday, hitting $0.37. The company had a trading volume of 39,606 shares, compared to its average volume of 3,672,514. Evogene has a 1-year low of $0.35 and a 1-year high of $1.33. The firm has a 50-day moving average price of $0.47 and a 200-day moving average price of $0.68.
Insider Activity
In other Evogene news, Director Leon Recanati bought 460,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average cost of $0.64 per share, for a total transaction of $294,400.00. Following the completion of the transaction, the director owned 1,343,886 shares in the company, valued at approximately $860,087.04. The trade was a 52.04% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.40% of the company’s stock.
Evogene Company Profile
Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.
Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies.
See Also
- Five stocks we like better than Evogene
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
